OOIR: Observatory of International Research

Papers

(The H4-Index of Gut is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Unusual history of ‘stitch’	1953
Response to McAlindon’s letter	1195
Innumerable nodules in all parts of the small intestine	454
Hepatocyte senescence in alcohol-associated hepatitis: epiphenomenon or disease-driving mechanism?	442
Defining the key intrahepatic gene networks in HCV infection driven by sex	302
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus	287
Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening	261
A mucus production programme promotes classical pancreatic ductal adenocarcinoma	248
Correction: P97 A patient information bundle outlining dietary advice in liver disease specific to the cost of living crisis improves patient care: ‘Looking after Your Liver for	240
Real-world evidence supports earlier treatment in HBeAg-positive but not HBeAg-negative chronic hepatitis B virus infection	235
Reassessing the prophylactic effect of clip closure to prevent delayed rebleeding after colorectal endoscopic submucosal dissection	231
Finding a mate for MLCK: improving the potential for therapeutic targeting of gut permeability	221
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B	214
Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials	210
Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges	206
Refining intergenerational MASLD risk: are measurement and mediation shaping the signal?	200
Picking up microbial clues in early-onset colorectal cancer	182
COVID-19 and liver disease	170
Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system	167
Methionine deficiency facilitates antitumour immunity by altering m⁶A methylation of immune checkpoint transcripts	163
Where are we with gastric cancer screening in Europe in 2024?	153
Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study	146
Current therapies and new developments in NASH	143
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation	139
Impact of margin thermal ablation after endoscopic mucosal resection of large (≥20 mm) non-pedunculated colonic polyps on long-term recurrence	139

Crohn’s disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset	137
IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells	135
Growth rates and histopathological outcomes of small (6–9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal	131
Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm	128
Liquid biopsy to identify Barrett’s oesophagus, dysplasia and oesophageal adenocarcinoma: the EMERALD multicentre study	128
Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction	127
Third Asia-Pacific consensus recommendations on colorectal cancer screening and postpolypectomy surveillance	127
S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos	126
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?	126
Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study	125
Need for standardised approaches to human microbiome research using the example of colorectal neoplasia research	125
Impact of climate change on vulnerable populations	120
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression	118
Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma	117
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma	114
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T _H 17 pathogenicity and transdifferentiation	114
Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD	113
Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditio	112
Rare cause of obstructive jaundice	111
Quantifying artificial sweeteners and emulsifiers in Crohn’s disease and its relationship with disease activity: the ENIGMA study – a novel and targeted approach	111
Endoscopic mucosal and submucosal cutting for long benign oesophageal strictures	110
Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment	107
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?	106
Lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis: more doubts than answers	105
Perplexing case of abdominal pain with eosinophilia and fasciitis	104
Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model	102
Correction: Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	102
Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19	101
Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies	98
New entity of adult ultra-short coeliac disease: the first international cohort and case–control study	97
Steatosis severity and metabolic fingerprints after HCV eradication: toward an individualised approach to HCC surveillance after HCV cure	96
Selective decontamination of the digestive tract in critically ill children: fighting fire with fire or burning down the house?	94
Intron-mediated enhancement of SPINK1 expression for pancreatitis therapy	94
Limitations of Helicobacter pylori single-method testing: evidence from a cohort study	93
Tumour-intrinsic alterations and stromal matrix remodelling promote Wnt-niche independence during diffuse-type gastric cancer progression	91
Decoding HBV-specific adaptive immunity: from natural clearance to cure	90
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance	89
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities	88
Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling	86
Unveiling 8 years of duodenoscope contamination: insights from a retrospective analysis in a large tertiary care hospital	82
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer	82
Association between appendectomy and Parkinson’s disease from the UK Biobank	78
Endoscopic stratification of gastric intestinal metaplasia: where are we, where do we want to go and how do we get there?	78
British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy	78
SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination	77
Environmental and healthcare trade-offs between single-use and reusable gastroscopes	76
Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine	76
Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?	75
Does the benefit of haemostatic powder differ by Forrest classification in non-variceal upper gastrointestinal bleeding?	74
Rethinking routine mapping biopsies in gastric intestinal metaplasia: justification for endoscopic stratification	74

Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?	74
GI highlights from the literature	74